133 related articles for article (PubMed ID: 35598099)
21. Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE).
Warren RB; Barker JNWB; Finlay AY; Burden AD; Kirby B; Armendariz Y; Williams R; Hatchard C; Khare S; Griffiths CEM
Br J Dermatol; 2020 Jul; 183(1):60-70. PubMed ID: 31628677
[TBL] [Abstract][Full Text] [Related]
22. The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials.
Langley RG; Feldman SR; Nyirady J; van de Kerkhof P; Papavassilis C
J Dermatolog Treat; 2015 Feb; 26(1):23-31. PubMed ID: 24354461
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.
Warren RB; Blauvelt A; Poulin Y; Beeck S; Kelly M; Wu T; Geng Z; Paul C
Br J Dermatol; 2021 Jan; 184(1):50-59. PubMed ID: 32594522
[TBL] [Abstract][Full Text] [Related]
24. Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response.
Rompoti N; Sidiropoulou P; Panagakis P; Stratigos A; Papoutsaki M; Stefanaki E; Vavouli C; Politou M; Befon A; Kostakis P; Rigopoulos D; Nicolaidou E
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1240-1247. PubMed ID: 31953892
[TBL] [Abstract][Full Text] [Related]
25. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
[TBL] [Abstract][Full Text] [Related]
26. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE).
Thaçi D; Humeniuk J; Frambach Y; Bissonnette R; Goodman JJ; Shevade S; Gong Y; Papavassilis C;
Br J Dermatol; 2015 Sep; 173(3):777-87. PubMed ID: 25823958
[TBL] [Abstract][Full Text] [Related]
27. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study.
Bagel J; Duffin KC; Moore A; Ferris LK; Siu K; Steadman J; Kianifard F; Nyirady J; Lebwohl M
J Am Acad Dermatol; 2017 Oct; 77(4):667-674. PubMed ID: 28780364
[TBL] [Abstract][Full Text] [Related]
28. Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study.
Blauvelt A; Pariser DM; Tyring S; Bagel J; Alexis AF; Soung J; Armstrong AW; Muscianisi E; Kianifard F; Steadman J; Sarkar RP; Garcet S; Krueger JG
J Dermatol Sci; 2023 Jan; 109(1):12-21. PubMed ID: 36690571
[TBL] [Abstract][Full Text] [Related]
29. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
Paul C; Lacour JP; Tedremets L; Kreutzer K; Jazayeri S; Adams S; Guindon C; You R; Papavassilis C;
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1082-90. PubMed ID: 25243910
[TBL] [Abstract][Full Text] [Related]
30. Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial.
Gottlieb AB; Kubanov A; van Doorn M; Sullivan J; Papp KA; You R; Regnault P; Frueh JA
Br J Dermatol; 2020 Apr; 182(4):889-899. PubMed ID: 31286480
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis.
Gisondi P; Rovaris M; Piaserico S; Girolomoni G
Br J Dermatol; 2020 Jan; 182(1):175-179. PubMed ID: 31004509
[TBL] [Abstract][Full Text] [Related]
32. A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results.
Magnolo N; Kingo K; Laquer V; Browning J; Reich A; Szepietowski JC; Keefe D; Mazur R; Ghelani P; Forrer P; Wraith L; Patekar M
J Am Acad Dermatol; 2022 Jan; 86(1):122-130. PubMed ID: 34555481
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis.
Soenen R; Wang Z; Grine L; Dreesen E; Schots L; Brouwers E; Declerck P; Thomas D; Lambert J
Clin Exp Dermatol; 2022 Jul; 47(7):1324-1336. PubMed ID: 35245966
[TBL] [Abstract][Full Text] [Related]
34. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.
Elewski BE; Puig L; Mordin M; Gilloteau I; Sherif B; Fox T; Gnanasakthy A; Papavassilis C; Strober BE
J Dermatolog Treat; 2017 Sep; 28(6):492-499. PubMed ID: 28266243
[TBL] [Abstract][Full Text] [Related]
35. Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis.
Teeple A; Fitzgerald T
J Dermatolog Treat; 2022 Feb; 33(1):518-524. PubMed ID: 32479140
[TBL] [Abstract][Full Text] [Related]
36. Secukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: Sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 study.
Bhat RM; Leelavathy B; Aradhya SS; Gopal MG; Pratap DV; Mubashir M; Srinivas P; Pande SY; Thavkar AS
Indian Dermatol Online J; 2017; 8(1):16-24. PubMed ID: 28217466
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.
Imafuku S; Honma M; Okubo Y; Komine M; Ohtsuki M; Morita A; Seko N; Kawashima N; Ito S; Shima T; Nakagawa H
J Dermatol; 2016 Sep; 43(9):1011-7. PubMed ID: 26919410
[TBL] [Abstract][Full Text] [Related]
38. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
39. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
Bissonnette R; Luger T; Thaçi D; Toth D; Lacombe A; Xia S; Mazur R; Patekar M; Charef P; Milutinovic M; Leonardi C; Mrowietz U
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1507-1514. PubMed ID: 29444376
[TBL] [Abstract][Full Text] [Related]
40. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
